Head and Neck Cancer Diagnostic Methods Market by Diagnostic Methods and Geography - Forecast and Analysis 2022-2026

The head and neck cancer diagnostics market share is expected to increase to USD 4.22 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 11.62%.

This head and neck cancer diagnostics market research report provide valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers head and neck cancer diagnostics market segmentation by diagnostic methods (biopsy and blood tests, imaging, endoscopy, and dental diagnostics) and geography (North America, Europe, Asia, and Rest of World (ROW)). The head and neck cancer diagnostics market report also offer information on several market vendors, including Accuray Inc., General Electric Co., AbbVie Inc., AdDent Inc., Bristol Myers Squibb Co., Canon Inc., Carestream Health Inc., Esaote Spa, Flexicare Group Ltd., FUJIFILM Holdings Corp., Hitachi Ltd., KARL STORZ SE and Co. KG, Koninklijke Philips NV, Merck KGaA, Neusoft Corp., Olympus Corp., Optim LLC, Shimadzu Corp., Siemens AG, and Xoran Technologies LLC among others.

What will the Head and Neck Cancer Diagnostics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Head and Neck Cancer Diagnostics Market Size for the Forecast Period and Other Important Statistics

Head and Neck Cancer Diagnostics Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a positive impact on the market growth during and post COVID-19 era. The increasing incidences of head and neck cancers is notably driving the head and neck cancer diagnostics market growth, although factors such as frequent product recalls may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the head and neck cancer diagnostics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Head and Neck Cancer Diagnostics Market Driver

• One of the key factors driving the global head and neck cancer diagnostics industry growth is the increasing incidences of head and neck cancers.
• This is attributed to SCC, which is usually diagnosed late with a poor prognosis and is especially among men having a history of alcohol consumption and tobacco use.
• HNSCC is sixth-leading cancer by incidence, with about half a million new cases every year.
• As of January 2020, head and neck cancers accounted for about 4% of all cancers in the US.
• In 2020, an estimated 562,328 persons worldwide were diagnosed with head and neck cancer. An estimated 15,050 deaths from head and neck cancer occurred in the US in 2020.
• According to the CDC, HPV causes about 70% of all oropharyngeal cancers in the US.
• According to the NHS, about 12,000 new cases of head and neck cancers are diagnosed annually in the UK. Such factors will drive the demand for head and neck cancer diagnostics during the forecast period.

Key Head and Neck Cancer Diagnostics Market Trend

• Rising use of immunotherapy in head and neck cancer treatment is one of the key head and neck cancer diagnostics market trends that is expected to impact the industry positively in the forecast period.
• Immunotherapy or biologic therapy aims to strengthen the body's natural defenses against cancer.
• The FDA has approved two immunotherapy medications, pembrolizumab (Keytruda), and nivolumab (Opdivo), for the treatment of persons who have recurrent or metastatic head and neck squamous cell carcinoma.
• KEYTRUDA is an immunotherapy that works with the patient's immune system to help to fight cancer. It can be used as a treatment if HNSCC has spread or returned, it cannot be surgically removed, and the tumor tests are positive for PD-L1.
• KEYTRUDA alone can be used as a treatment if HNSCC has spread or returned, and the patient has received chemotherapy containing platinum that did not work or is no longer working. Such developments are expected to drive market growth during the forecast period.

Key Head and Neck Cancer Diagnostics Market Challenge

• One of the key challenges to the global head and neck cancer diagnostics industry growth is the frequent product recalls.
• The global head and neck cancer diagnostics market includes various equipment such as PET scans, CT scans, MRIs, and laryngoscopy equipment.
• There are instances where the medical equipment must be checked, adjusted, or fixed to ensure that it does not fail unexpectedly or violate regulatory guidelines.
• In the US, the FDA is responsible for updating the Medical Device Recall Database after a company has initiated a correction or removal of its equipment.
• In April 2022, GE Healthcare initiated a product recall for its 1.5t Signa Horizon Lx Magnetic Resonance System, owing to a failure to have proper venting could present a safety issue if the cryogen gas is vented into the MR room during a magnet quench, potentially depriving the room of oxygen.
• In July 2021, GE Healthcare initiated a product recall for its Class 2 Device Recall SIGNA PET/MR. Such frequent product recalls adversely affect the manufacturer and negatively impact the market growth.

This head and neck cancer diagnostics market analysis report also provide detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global head and neck cancer diagnostics market as a part of the global healthcare equipment market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the head and neck cancer diagnostics market during the forecast period.

Who are the Major Head and Neck Cancer Diagnostics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• Accuray Inc.
• General Electric Co.
• AbbVie Inc.
• AdDent Inc.
• Bristol Myers Squibb Co.
• Canon Inc.
• Carestream Health Inc.
• Esaote Spa
• Flexicare Group Ltd.
• FUJIFILM Holdings Corp.
• Hitachi Ltd.
• KARL STORZ SE and Co. KG
• Koninklijke Philips NV
• Merck KGaA
• Neusoft Corp.
• Olympus Corp.
• Optim LLC
• Shimadzu Corp.
• Siemens AG
• Xoran Technologies LLC

This statistical study of the head and neck cancer diagnostics market encompasses successful business strategies deployed by the key vendors. The head and neck cancer diagnostics market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.

Product Insights and News

• Accuray Inc. - The company offers head and neck cancer diagnostics such as TomoTherapy and Radixact systems. 
• Accuray Inc. - In October 2021, the company signed an agreement designed to enhance the Accuray Radixact System's ability to treat breast cancer with C RAD AB. 

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The head and neck cancer diagnostics market forecast report offer in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Head and Neck Cancer Diagnostics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the head and neck cancer diagnostics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Head and Neck Cancer Diagnostics Market?

For more insights on the market share of various regions Request for a FREE sample now!

41% of the market's growth will originate from North America during the forecast period. The US is the key markets for head and neck cancer diagnostics in North America. Market growth in this region will be faster than the growth of the market in Europe.

The presence of established vendors, increasing awareness about HPV-related diseases, and the presence of dedicated programs for treating head and neck cancers will facilitate the head and neck cancer diagnostics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 affected the healthcare systems regionally and also had a significant impact on the head and neck cancer diagnostics market. The rise in the number of COVID-19 cases in countries across North America compelled governments to introduce emergency legislation, which included restrictions on several business activities. However, the market recovered in 2021 due to the lifting of lockdowns and the initiation of large-scale vaccination drives. Moreover, vendors are trying to introduce products in the market that can cater to the specific needs of healthcare facilities triggered by the COVID-19 pandemic. Such factors will increase the demand for head and neck cancer diagnostics in the region during the forecast period.

What are the Revenue-generating Diagnostic Methods Segments in the Head and Neck Cancer Diagnostics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The head and neck cancer diagnostics market share growth by the biopsy and blood tests segment will be significant during the forecast period. Biopsies are done for diagnosing cancer. Biopsy for head and neck cancer diagnostics include incisional biopsy, fine-needle aspiration (FNA) biopsy, and human papillomavirus (HPV) testing. As biopsies and blood tests can be carried out even after performing other diagnostic methods, this segment is expected to contribute the largest revenue share to the global head and neck cancer diagnostics market during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the head and neck cancer diagnostics market size and actionable market insights on post COVID-19 impact on each segment.

You may be interested in:

Cancer Diagnostic Devices market - The market size will grow up to USD 6.05 billion at a CAGR of 7.58% during 2021-2025.

Cervical Cancer Diagnostic Testing market - The market size has the potential to grow by USD 2.13 billion during 2019-2024, and the market's growth momentum will accelerate during the forecast period.

Request for a FREE sample

What are the Key Data Covered in this Head and Neck Cancer Diagnostics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive head and neck cancer diagnostics market growth during the next five years
• Precise estimation of the head and neck cancer diagnostics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the head and neck cancer diagnostics industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of head and neck cancer diagnostics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch